CN V3 Blog - Consultant's Corner - Mini Blog

Article

Mr. Paivanas is the President and Founding Director of Thomas A. Paivanas & Associates (TAP&A) and has over 25 years of experience in the health care field.  The firm specializes in assisting clients in realizing particularly difficult oncology and health care opportunities and challenges.  Areas of interest and expertise include oncology program integration across multi-institutional venues, strategic business planning for stem cell transplantation, academic and community hospital partnering, primary market research for pharmaceutical industry, strategic planning for private and faculty physician's practices, practice mediation, strategic business planning for biotech companies, and comprehensive community cancer program development.

Thomas A. Paivanas, MHSA paivanas@verizon.net

Mr. Paivanas is the President and Founding Director of Thomas A. Paivanas & Associates (TAP&A) and has over 25 years of experience in the health care field.  The firm specializes in assisting clients in realizing particularly difficult oncology and health care opportunities and challenges.  Areas of interest and expertise include oncology program integration across multi-institutional venues, strategic business planning for stem cell transplantation, academic and community hospital partnering, primary market research for pharmaceutical industry, strategic planning for private and faculty physician's practices, practice mediation, strategic business planning for biotech companies, and comprehensive community cancer program development.

Martin Neltner mneltner@earthlink.net

Martin Neltner is the President and Founder of Neltner Billing and Consulting, a full-service medical management with particular expertise in oncology. Mr. Neltner, a nationally recognized practice management and billing specialist, has testified before congressional committees and the AMA regarding financial issues affecting the delivery of cancer care. He is an avid health care blogger and has written numerous white papers as well as articles and abstracts appearing in peer review publications. Mr. Neltner regularly conducts seminars across the country on topics such as coding, documentation, reimbursement, cancer care management and options for negotiating contractual arrangements.

Recent Videos
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
3 experts in this video
3 experts in this video
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Related Content